I published a preprint in December 2018: ˝Role of the Th17 cells in the pathophysiology of multiple sclerosis˝.

DOI:

  • 10.13140/RG.2.2.32248.29448

What is your opinion on the role of the Th17 cells in the pathophysiology of multiple sclerosis?

Do you have any experience in the use of secukinumab (anti-IL17A) and ustekinumab (blocks IL12/23, but it has to be reengineered to pass the blood-brain barrier for the use in multiple sclerosis, possibly effective only in the early stage)?

Thank you all in advance!

Similar questions and discussions